NeuroDerm Ltd.

Industry · 14 registered clinical trials.

Status	Trial	Phase	Started
Active Not Recruiting	Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Parkinson's Disease	Phase 3	2019-09-30
Withdrawn	A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Admin Parkinson	Phase 3	2018-04-10
Withdrawn	A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusi Parkinson's Disease	Phase 3	2016-08-01
Active Not Recruiting	A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease Parkinson's Disease	Phase 2	2016-05-04
Completed	A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Dis Parkinson's Disease	Phase 2	2015-12-29
Completed	A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects Parkinson's Disease	Phase 1	2015-05-29
Completed	A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbid Parkinson's Disease	Phase 1	2015-04-01
Completed	A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinso Parkinson's Disease	Phase 1	2014-08-11
Completed	A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treat Parkinson's Disease	Phase 2	2014-01-06
Completed	A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease	Phase 1	2012-12-16
Completed	Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers Parkinson's Disease	Phase 1	2012-04-30
Completed	A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodo Parkinson's Disease	Phase 1 / Phase 2	2011-01-01
Completed	A Study of ND0801 in Attention Deficit/Hyperactivity Disorder (ADHD) Attention Deficit and Hyperactivity Disorder	Phase 1 / Phase 2	2010-10-01
Completed	Safety, Tolerability and Pharmacokinetic Profile of Levodopa Administered With Continuous Administration of ND Parkinson's Disease	Phase 1	2010-04-01